In a promising development for the treatment of neurodegenerative disorders, researchers at the Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), have identified drug candidates that may offer new avenues for managing conditions like Alzheimer’s and Parkinson’s disease.
Published in the journal Drug Discovery Today, the study emphasizes the therapeutic potential of peptidomimetics—synthetic compounds designed to imitate the structure and function of natural proteins—in fostering neuronal growth and ensuring the survival of nerve cells.
Peptidomimetic compounds are being investigated as alternatives to neurotrophins, the natural proteins vital for the health and function of neurons. While neurotrophins have shown potential in treating neurodegenerative conditions, their instability and tendency to degrade rapidly have limited their clinical use.
To overcome these challenges, the IASST research team has been working on peptidomimetics that can replicate the biological activity of neurotrophins. These synthetic molecules offer significant advantages, such as enhanced stability and bioavailability, allowing them to reach the brain more effectively and maintain therapeutic efficacy for longer periods.
“Neurotrophin peptidomimetics are tailored to activate specific biological responses and are valuable tools in drug development, especially where natural peptides fall short due to issues like poor oral absorption or rapid breakdown,” explained the research group led by Professor Ashis K. Mukherjee.
An additional benefit of these compounds lies in their ability to target specific receptors with higher precision, potentially minimizing unwanted side effects.
The research delves into the signaling mechanisms responsible for neuronal development and protection, identifies promising pharmacological targets, and assesses how peptidomimetics might be applied in clinical therapies for neurodegenerative illnesses.
The team also looked into the broader applications of these compounds, including their possible repurposing for other diseases such as cancer, and the development of new drug prototypes modeled after neurotrophin mimetics.
According to the researchers, peptidomimetics hold significant promise and may play a crucial role in the future of treatment for neurodegenerative diseases, offering renewed hope for patients and healthcare providers alike.